Remission, low disease activity and improvement of pain and function in psoriatic arthritis patients treated with IL-12/23 and IL-17 inhibitors. A multicenter prospective study

Remission, low disease activity and improvement of pain and function in psoriatic arthritis patients treated with IL-12/23 and IL-17 inhibitors. A multicenter prospective study

The development of new biologic and targeted synthetic DMARDs can lead to good disease control. The aim of the present study was to assess the rate of remission and low disease activity, and the improvement of pain and function, in psoriatic arthritis (PsA) patients treated with new anti-IL-12/23 an...

Full description

Bibliographic Details
Main Authors: F.M. Perrotta, A. Delle Sedie, S. Scriffignano, P. Volpe, E. Cordisco, N. Milano, M. Gabini, E. Lubrano
Format: Article
Language:English
Published: PAGEPress Publications 2020-04-01
Series:Reumatismo
Subjects:
Psoriatic arthritis
remission
anti-IL12/23
anti-IL-17.
Online Access:https://www.reumatismo.org/index.php/reuma/article/view/1266

Similar Items

Similar Items